Cargando…
Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study
BACKGROUND: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a score summarising the features of GHD and evaluate its ability to measure the e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810096/ https://www.ncbi.nlm.nih.gov/pubmed/29433573 http://dx.doi.org/10.1186/s12902-018-0237-3 |
_version_ | 1783299686804750336 |
---|---|
author | Kann, Peter H. Bergmann, Simona Bidlingmaier, Martin Dimopoulou, Christina Pedersen, Birgitte T. Stalla, Günter K. Weber, Matthias M. Meckes-Ferber, Stefanie |
author_facet | Kann, Peter H. Bergmann, Simona Bidlingmaier, Martin Dimopoulou, Christina Pedersen, Birgitte T. Stalla, Günter K. Weber, Matthias M. Meckes-Ferber, Stefanie |
author_sort | Kann, Peter H. |
collection | PubMed |
description | BACKGROUND: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a score summarising the features of GHD and evaluate its ability to measure the effect of GH substitution in AGHD. METHODS: The Growth hormone deficiency and Efficacy of Treatment (GET) score (0–100 points) assessed (weighting): HRQoL (40%), disease-related days off work (10%), bone mineral density (20%), waist circumference (10%), low-density lipoprotein cholesterol (10%) and body fat mass (10%). A prospective, non-interventional, multicentre proof-of-concept study investigated whether the score could distinguish between untreated and GH-treated patients with AGHD. A 10-point difference in GET score during a 2-year study period was expected based on pre-existing knowledge of the effect of GH substitution in AGHD. RESULTS: Of 106 patients eligible for analysis, 22 were untreated GHD controls (9 females, mean ± SD age 52 ± 17 years; 13 males, 57 ± 13 years) and 84 were GH-treated (31 females, age 45 ± 13 years, GH dose 0.30 ± 0.16 mg/day; 53 males, age 49 ± 15 years, GH dose 0.25 ± 0.10 mg/day). Follow-up was 706 ± 258 days in females and 653 ± 242 days in males. The GET score differed between the untreated control and treated groups with a least squares mean difference of + 10.01 ± 4.01 (p = 0.0145). CONCLUSIONS: The GET score appeared to be a suitable integrative instrument to summarise the clinical features of GHD and measure the effects of GH substitution in adults. Exercise capacity and muscle strength/body muscle mass could be included in the GET score. TRIAL REGISTRATION: NCT number: NCT00934063. Date of registration: 02 July 2009. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12902-018-0237-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5810096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58100962018-02-16 Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study Kann, Peter H. Bergmann, Simona Bidlingmaier, Martin Dimopoulou, Christina Pedersen, Birgitte T. Stalla, Günter K. Weber, Matthias M. Meckes-Ferber, Stefanie BMC Endocr Disord Research Article BACKGROUND: The adverse effects of growth hormone (GH) deficiency (GHD) in adults (AGHD) on metabolism and health-related quality of life (HRQoL) can be improved with GH substitution. This investigation aimed to design a score summarising the features of GHD and evaluate its ability to measure the effect of GH substitution in AGHD. METHODS: The Growth hormone deficiency and Efficacy of Treatment (GET) score (0–100 points) assessed (weighting): HRQoL (40%), disease-related days off work (10%), bone mineral density (20%), waist circumference (10%), low-density lipoprotein cholesterol (10%) and body fat mass (10%). A prospective, non-interventional, multicentre proof-of-concept study investigated whether the score could distinguish between untreated and GH-treated patients with AGHD. A 10-point difference in GET score during a 2-year study period was expected based on pre-existing knowledge of the effect of GH substitution in AGHD. RESULTS: Of 106 patients eligible for analysis, 22 were untreated GHD controls (9 females, mean ± SD age 52 ± 17 years; 13 males, 57 ± 13 years) and 84 were GH-treated (31 females, age 45 ± 13 years, GH dose 0.30 ± 0.16 mg/day; 53 males, age 49 ± 15 years, GH dose 0.25 ± 0.10 mg/day). Follow-up was 706 ± 258 days in females and 653 ± 242 days in males. The GET score differed between the untreated control and treated groups with a least squares mean difference of + 10.01 ± 4.01 (p = 0.0145). CONCLUSIONS: The GET score appeared to be a suitable integrative instrument to summarise the clinical features of GHD and measure the effects of GH substitution in adults. Exercise capacity and muscle strength/body muscle mass could be included in the GET score. TRIAL REGISTRATION: NCT number: NCT00934063. Date of registration: 02 July 2009. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12902-018-0237-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-13 /pmc/articles/PMC5810096/ /pubmed/29433573 http://dx.doi.org/10.1186/s12902-018-0237-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kann, Peter H. Bergmann, Simona Bidlingmaier, Martin Dimopoulou, Christina Pedersen, Birgitte T. Stalla, Günter K. Weber, Matthias M. Meckes-Ferber, Stefanie Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study |
title | Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study |
title_full | Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study |
title_fullStr | Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study |
title_full_unstemmed | Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study |
title_short | Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study |
title_sort | design of the growth hormone deficiency and efficacy of treatment (get) score and non-interventional proof of concept study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810096/ https://www.ncbi.nlm.nih.gov/pubmed/29433573 http://dx.doi.org/10.1186/s12902-018-0237-3 |
work_keys_str_mv | AT kannpeterh designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT bergmannsimona designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT bidlingmaiermartin designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT dimopoulouchristina designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT pedersenbirgittet designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT stallagunterk designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT webermatthiasm designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy AT meckesferberstefanie designofthegrowthhormonedeficiencyandefficacyoftreatmentgetscoreandnoninterventionalproofofconceptstudy |